KarXT

success failure signposts
Biotech

Neurocrine's KarXT rival hits in phase 2—but only at low dose

Neurocrine achieved its hoped-for profile in the schizophrenia trial but only saw efficacy at the lowest dose—the three higher doses all failed.
Nick Paul Taylor Aug 28, 2024 7:53am
BMS flag

BMS' schizophrenia drug shows long-term benefit with new data

Apr 6, 2024 1:15pm
christmas cash gift money present holiday

UPDATE: Bristol Myers Squibb unwraps $14B deal for Karuna

Dec 22, 2023 7:32am
journey path light sunshine stairs climb reach

Karuna's schizophrenia drug set for FDA decision in Q3 2024

Nov 29, 2023 10:00am
long time journey steps difficult alone solitary

Karuna's journey from 'serendipitous clinical finding' to FDA

Oct 4, 2023 6:00am
On target clinical trial success bullseye score

Hype builds for Karuna's schizophrenia drug with phase 3 data

Mar 20, 2023 12:03pm